0 Comments
0 Shares
1347 Views
Search
Discover new people, create new connections and make new friends
- Please log in to like, share and comment!
- The "PD-1 Patent Cliff" Countdown: How 2026 is Preparing for the Next Big Wave.In late 2026, the industry is pivoting toward "Immuno-Oncology (IO) Preparation." This year, a radical new wave of R&D is focused on the impending 2028 patent expirations of blockbuster PD-1 inhibitors like Keytruda and Opdivo. This innovation is a primary driver for the market, as these "Checkpoint Inhibitors" currently represent the largest segment of oncology spending worldwide. Using...0 Comments 0 Shares 292 Views
- The Rise of "Interchangeability": A Game-Changer for Patient AccessIn the world of biosimilars, "interchangeability" is the ultimate regulatory gold standard. While all biosimilars are as safe and effective as their reference products, an interchangeable designation means the manufacturer has provided additional data to prove that switching between the two products multiple times will not cause any adverse effects. This designation is crucial because it allows...0 Comments 0 Shares 1803 Views
- Wilsons Disease Market4 gene therapy trials showing curative potential for hepatic copper in 2026 As 2026 begins, the global hepatology community is closely monitoring a wave of breakthrough data from Phase II and III trials that aim to permanently correct the ATP7B genetic mutation. Regulatory authorities in the European Union and the United States have recently signaled a willingness to accept biomarker-driven...0 Comments 0 Shares 1401 Views